Anastasios Stathis

Medical Oncologist. Head-Phase I Program, Oncology Institute of Southern Switzerland. Professor-Università della Svizzera Italiana.

[IND Program CCTG @INDProgramCCTG]

MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO

https://t.co/RZdCpG0iWG

[Diogo Martins Branco @DMBranco]

Great session this afternoon on #oncology #drug development 💉💊
#Biotech status & prospects
Fruitful live discussion & interaction
#ESMOTAT24

[Lillian Siu @lillian_siu]

#ESMOTAT2023 starting. Amazing agenda and very excited to see so many attendees from all over the world in this important drug development meeting👏👏👏

[ESMO - Eur. Oncology @myESMO]

ESMO announces Funda Meric-Bernstam as the recipient of 2024 TAT Honorary Award for her outstanding contributions to #PrecisionOncology.

📅 She will deliver her award lecture on 26 February at the #ESMOTAT24 in Paris

📌https://t.co/tU4ihu42zE.

[ESMO - Eur. Oncology @myESMO]

#ESMOTAT24: Early registration deadline 📢⏲️ 10 January 2024 at 23:59 (CET). Watch @LSeymourMD, Shivaani Kummar, Irene Braña, Timothy Yap, @lillian_siu, @ElenaGarralda & @AnastasiosStat2 give their takes on why you should attend. 👇
https://t.co/Z7y9otbFyQ

[Anastasios Stathis @AnastasiosStat2]

@thanosplevris Αραγε τι σημαια έχεις κρεμασμένη εσυ στο σπίτι σου κύριε (με ποια προσόντα;) πρώην υπουργέ υγείας;

[ESMO - Eur. Oncology @myESMO]

#ESMOTAT24: Last few hours to make sure you are part of this international multi-stakeholder forum in the early drug development arena. ⏰Abstract submission deadline today (28/11, 21:00 CET)
https://t.co/x14Z9dn28y

@lillian_siu @ElenaGarralda @AnastasiosStat2

[Anastasios Stathis @AnastasiosStat2]

@thanosplevris Και μετά ήρθαν οι φίλοι σου οι ναζί

[ESMO - Eur. Oncology @myESMO]

#ESMOTAT24: Be part of this international multi-stakeholder forum in the early drug development arena! Merit travel grants are available. ⏰Abstract submission deadline: 28 November 2023.
https://t.co/Flg1468uaH

@lillian_siu @ElenaGarralda @AnastasiosStat2

[ESMO - Eur. Oncology @myESMO]

#ESMOTAT24: Shape the future of cancer #drugdevelopment and take part in this unique forum gathering all relevant stakeholders in #oncology. ⏰Abstract submission deadline: 28 November 2023.
https://t.co/lsqGSsH3Rq

@lillian_siu @ElenaGarralda @AnastasiosStat2

[Anastasios Stathis @AnastasiosStat2]

@PrimeministerGR Πόσοι άνθρωποι έχασαν την ζωή τους κ Πρωθυπουργέ;

[Lillian Siu @lillian_siu]

#ESMOTAT24 taking place Feb 26-28, 2024, in Paris! Abstract submission now open till Nov 28, 2023: https://t.co/DyPdB0b9xO @myESMO
New meeting features with parallel industry sessions - not to be missed

[Anastasios Stathis @AnastasiosStat2]

@Dora_Bakoyannis Συγχαρητήρια, πολύ συγκινητικό. Καμία φωτια θα σβησετε;

[Ente Ospedaliero Cantonale @EnteOspedaliero]

Dall’EOC cinque nuovi Professori titolari per la Facoltà di scienze biomediche dell’USI.
Comunicato stampa: https://t.co/4bRTIoAkRG

[Anastasios Stathis @AnastasiosStat2]

@thanosplevris Ακόμα δεν έχω καταλάβει για ποιον λόγο είστε υπουργός υγείας στην Ελλάδα.

[Anastasios Stathis @AnastasiosStat2]

@thanosplevris Το σύστημα υγείας στην Ελλάδα είναι κατεστραμμένο και έχετε τεράστια ευθύνη και εσείς και οι φίλοι σας διοικητές των νοσοκομείων (που γίνονται φυσικά διοικητές μόνο επειδή φίλοι σας)

[International Conference on Malignant Lymphoma @icmlugano]

📢🗓The #17ICML Scientific Program, based on more than 800 submitted abstracts, is almost ready!
Watch the video to have a sneak peek of the 17-ICML and stay tuned!

[Anastasios Stathis @AnastasiosStat2]

@MakisVoridis Και καλή λευτεριά σύντομα από την φασιστική σας κυβέρνηση

[Francesco Bertoni @frbertoni]

The abstract of the other one of our two #AACR23 #lymphoma posters. @IOR_Bellinzona @USI_en @EnteOspedaliero @CascioneLuciano @AnastasiosStat2 @SpexisAg
Adding CXCR4 inhibition to improve activity of anti-lymphoma agents:
https://t.co/BGhm68s1z3

[Francesco Bertoni @frbertoni]

The abstract of one of our two #AACR23 #lymphoma posters. @IOR_Bellinzona @USI_en @EnteOspedaliero @CascioneLuciano @AnastasiosStat2 @ManelEsteller
ERBB4 as resistance to BTK and PI3K inhibitors in lymphomas:
https://t.co/amUYwAoaWn